An apparel company whose mission is to encourage people to live their lives to the fullest potential by embracing and enjoying each and every day.  10% of all proceeds are donated to GForce.

Hark is on a mission to share the real story of ALS and to provide a network of compassionate resources for families.  They provide assistance to alleviate the financial burdens faced by families battling ALS.

Help provide individuals with neuromuscular diseases or injuries with leading edge technology, equipment and services.

Create a global conversation about ALS to ultimately find solutions and an end to the disease..

Raise public awareness toward ALS by providing and documenting extraordinary life adventures for individuals with muscular diseases or injuries.

To equip, encourage, and empower people living with ALS; the Brigance Brigade Foundation improves the quality of life for PALS and their families by providing access to need equipment, resource guidance, and support services.

Project Main St. strives to improve the quality of life for individuals afflicted with ALS and their families by lessening the financial burden associated with this dreadful disease.

Very comprehensive ALS technology guide for patients living with the disease.

The ALS Therapy Development Institute and its scientists actively discover and develop treatments for ALS.  They are the world’s first and largest nonprofit biotech focused 100% on ALS research.  Led by people with ALS and drug development experts, they understand the urgent need to slow and stop this disease.

Our mission is to fund and support ALS research around the world.  Our goal is to find a cure.

A nonprofit whose mission is to discover cures and treatments for ALS, Alzheimer’s and Parkinson’s from plants.  Their current ALS treatment in clinical trials is L-serine.

Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics that address critical unmet needs in the treatment of neurodegenerative diseases.  Their lead product, NP001, will complete Phase 2B at the end of 2017.  They expect to seek approval with the FDA if study results support previous clinical trial findings.


Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Their lead ALS products are Tirasemtiv and CK-107, both fast skeletal muscle troponin activators.